[Ip-health] European Public Health Advocates Demand Greater Public Returns From European Commission's Research and Development Programme, Horizon 2020

James Still James at haiweb.org
Thu Feb 2 06:33:03 PST 2017


Dear IP Health,

Health Action International has today released a joint position paper
calling upon the European Commission to make substantial changes to how it
funds research and development (R&D) projects for new medicines, to allow
for greater public access to the innovations that it helps to fund. The
position paper particularly focuses on the EU’s R&D programme, Horizon
2020, which administers a funding pool of near €80 billion.

The position paper also echoes many of the demands made on Tuesday by the
European Parliament Committee on Environment, Public Health and Food
Safety.

The paper was co-authored by Health Action International, Médecins Sans
Frontières - Access Campaign, Global Health Advocates, Commons Network,
Universities Allied for Essential Medicines, Salud for Derecho, Knowledge
Ecology International – Europe and BukoPharmaKampagne.

To read the full report, go to http://bit.ly/2jYEAly.The media release is
available below and at http://bit.ly/2ktaY3e.

Kind regards,

-- 
James Still
Communications Advisor
Health Action International
Overtoom 60-2, 1054 HK Amsterdam, The Netherlands
Phone: + 31 (0) 20 412 4523
www.haiweb.org

________________________________________

PRESS RELEASE      
                   
For immediate release
Thursday 2 February, 2017

EUROPEAN PUBLIC HEALTH ADVOCATES DEMAND GREATER PUBLIC RETURNS FROM
EUROPEAN COMMISSION’S RESEARCH AND DEVELOPMENT PROGRAMME, HORIZON 2020

AMSTERDAM—European public health advocates have called upon the European
Commission to make substantial changes to how it funds research and
development (R&D) projects for new medicines, to allow for greater public
access to the innovations that it helps to fund.

“Europeans have a right to question why they are funding R&D projects
without the European Commission taking simple steps to guarantee that
citizens can benefit from discoveries that they helped to fund,” said
Tessel Mellema from Health Action International, speaking on behalf of the
eight civil society organisations who drafted a joint submission to the
Commission.

The call comes following the Commission’s public consultation for the
mid-term review of the European Union’s (EU) Research and Innovation
programme, Horizon 2020 (H2020), which administers a funding pool of
nearly €80 billion. It also echoes similar demands made on Tuesday by the
European Parliament Committee on Environment, Public Health and Food
Safety.

“At a time when there is real concern within Member States over
astronomical prices for new drugs treating cancer and hepatitis C, the
European Commission has the opportunity to take real and practical steps
to make new biomedical discoveries affordable and accessible across the
European Union,” said Aliénor Devalière, one of the report’s authors from
Médecins Sans Frontières - Access Campaign.

The joint submission to the Horizon 2020 consultation established six key
recommendations that the European Commission should consider during their
review process:

1.  Invest more public funding in biomedical R&D
2.  Improve public health needs-driven priority setting for biomedical R&D
3.  Improve and mandate open access publishing and open data
4. Ensure public return on public investment and safeguard equitable
access to publicly funded health technologies
5.  Explore alternative incentive mechanisms for more efficient,
high-quality R&D
6.  Increase transparency of research consortium agreements

The submission authors also highlight that the EU has an obligation to
ensure a high standard of human health protection across the Union,
however major inequalities still exist in the quality of healthcare
available in EU Member States.

The full submission to the European Commission consultation can be viewed
online at http://bit.ly/2jYEAly.

NOTE: The submission to the mid-term review of Horizon 2020 was
co-authored by the following organisations:
Health Action International
Medicines Sans Frontieres - Access Campaign
Global Health Advocates
Commons Network
Universities Allied for Essential Medicines
Salud por Derecho
Knowledge Ecology International - Europe
BukoPharmaKampagne

It has also been endorsed by the following organisations:
AIDS Action Europe
Grupo de Ativistas em Tratamentos
Ärzte der Welt e.V. (Doctors of the World Germany)
All-Ukrainian Network of People Living with HIV/AIDS
European Public Health Alliance
WEMOS
Hepatitis Scotland
Dying for a Cure
Praksis
Test-Aankoop
BEUC
Just Treatment
Health Projects for Latvia
EKPIZA
Brot für die Welt
OCU - Organización de Consumidores y Usuarios



More information about the Ip-health mailing list